Jonathan Harper, MD
Urology · Seattle, WANPI 1336358274
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,235 of the $12,464 with a category attached, or 66.1%. Boston Scientific accounts for 80.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $9,558, more than ten times the $871 reported in 2019.
Across 27 payments — averaging $461.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- C. R. Bard, Inc. & Subsidiaries$1K
- Intuitive Surgical$750
- Cook Medical LLC$126
- Urogen Pharma, Inc.$112
- 180 Medical, Inc.$29
- plus $21 from 2 others
What the payments were for
- Consulting fees$8,23566%
- Speaking & faculty fees$1,40011%
- Travel & lodging$1,1129%
- Food & beverage$9638%
- Education$7546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $10,011 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $1,415 |
| Intuitive Surgical | 1 | $750 |
| Cook Medical LLC | 1 | $126 |
| Urogen Pharma, Inc. | 1 | $112 |
| 180 Medical, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$7,798
- GENERAL - THERAPIES$1,652
- Da Vinci Surgical System$750
- LithoVue$148
- LITHO 150$126
- JELMYTO$112
How this compares
$12,464 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 12 | $1,539 |
| Tamsulosin Hcl | 15 | $159 |
Paid to pharmacies, not to this prescriber.
Other urology in Seattle
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Vi NguyenSeattle$53K
- Rogerio HuangSeattle$45K
- Cristopher GarlitzSeattle$45K
- Sarah PsutkaSeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.